Protease-Resistant Neurotrophic Peptide Mutant
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of the proNGF-A peptide for therapeutic use is hindered by its sensitivity to endocellular proteases, which leads to proteolytic digestion and conversion into the neurotoxic proNGF-B variant, making large-scale production challenging due to degradation and loss of bioactivity.
Innovation Solution
A mutant peptide, hproNGF-A A73Y/KG-RG, is developed with specific amino acid substitutions (A73Y, K175G, and R176G) that confer resistance to endocellular and extracellular proteases, maintaining neurotrophic and neuroprotective activity while preventing conversion into the neurotoxic form.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If native proNGF-A peptide is produced at large scale, then therapeutic availability increases, but proteolytic digestion by endocellular proteases converts it into neurotoxic proNGF-B variant
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of proNGF-A through site-directed mutagenesis. Specifically, three amino acid substitutions are introduced: Alanine to Tyrosine at position 73 (A73Y), Lysine to Glycine at position 175 (K175G), and Arginine to Glycine at position 176 (R176G). These sequence parameter changes confer resistance to endocellular proteases while maintaining the peptide's neurotrophic activity, thereby enabling stable large-scale production without conversion to the neurotoxic proNGF-B variant
2Reliability
If protease resistance is enhanced through amino acid substitutions, then peptide stability improves, but sequence modification may alter biological activity
Solution Approach 1:
The patent applies local quality by making targeted amino acid substitutions at specific positions (73, 175, and 176) within the proNGF-A sequence. These localized modifications are strategically chosen to interfere with protease recognition and cleavage sites while preserving the overall three-dimensional structure and bioactive regions of the peptide. The A73Y substitution targets N-terminal protease susceptibility, while K175G and R176G substitutions address C-terminal protease vulnerability, thereby achieving comprehensive protease resistance without compromising neurotrophic function
Data Source
AI summary
A protease-resistant neurotrophic peptide is provided. A pharmaceutical composition including the protease-resistant neurotrophic peptide in a pharmaceutically acceptable carrier, in combination with optional adjuvants, stabilizers and/or preservatives, is also provided.